JSSH
BCRX icon

J. Safra Sarasin Holding’s BioCryst Pharmaceuticals BCRX Stock Holding History

J. Safra Sarasin Holding’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
+15,700
New +$142K ﹤0.01% 756

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

J. Safra Sarasin Holding's BCRX Position: Q2 2026 in Review

J. Safra Sarasin Holding opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 15,700 shares worth $157K. The stake represents ﹤0.01% of the portfolio and ranks #756 among its holdings.

318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • J. Safra Sarasin Holding held 15,700 shares of BioCryst Pharmaceuticals worth $157K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new J. Safra Sarasin Holding position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #756 holding.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.